XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · Real-Time Price · USD
0.9030
-0.0470 (-4.95%)
Apr 1, 2025, 4:00 PM EDT - Market closed

XORTX Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Jan '22 Dec '20 2019 - 2015
Selling, General & Admin
2.192.281.931.220.51
Upgrade
Research & Development
0.182.426.760.680.28
Upgrade
Operating Expenses
2.624.969.242.311.1
Upgrade
Operating Income
-2.62-4.96-9.24-2.31-1.1
Upgrade
Interest Expense
----0-0.01
Upgrade
Interest & Investment Income
0.120.250.1--
Upgrade
Currency Exchange Gain (Loss)
-0.07-0.01-0-0.010
Upgrade
Other Non Operating Income (Expenses)
-0.752.551.420.75-0.2
Upgrade
EBT Excluding Unusual Items
-3.31-2.16-7.72-1.58-1.31
Upgrade
Asset Writedown
-----0.06
Upgrade
Other Unusual Items
----0.09
Upgrade
Pretax Income
-3.31-2.16-7.72-1.58-1.28
Upgrade
Net Income
-3.31-2.16-7.72-1.58-1.28
Upgrade
Net Income to Common
-3.31-2.16-7.72-1.58-1.28
Upgrade
Shares Outstanding (Basic)
32111
Upgrade
Shares Outstanding (Diluted)
32111
Upgrade
Shares Change (YoY)
45.25%33.91%35.25%47.77%24.34%
Upgrade
EPS (Basic)
-1.15-1.09-5.22-1.44-1.73
Upgrade
EPS (Diluted)
-1.15-1.09-5.22-1.44-1.73
Upgrade
Free Cash Flow
-3.68-6.59-8.98-4.8-0.73
Upgrade
Free Cash Flow Per Share
-1.28-3.32-6.07-4.39-0.98
Upgrade
EBITDA
-2.5-4.88-9.22-2.3-1.08
Upgrade
D&A For EBITDA
0.120.070.020.010.02
Upgrade
EBIT
-2.62-4.96-9.24-2.31-1.1
Upgrade
Updated Nov 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q